AR062644A1 - Tecnologia de suministro programable flotante - Google Patents

Tecnologia de suministro programable flotante

Info

Publication number
AR062644A1
AR062644A1 ARP070103903A ARP070103903A AR062644A1 AR 062644 A1 AR062644 A1 AR 062644A1 AR P070103903 A ARP070103903 A AR P070103903A AR P070103903 A ARP070103903 A AR P070103903A AR 062644 A1 AR062644 A1 AR 062644A1
Authority
AR
Argentina
Prior art keywords
programmable supply
supply technology
core
relates
floating
Prior art date
Application number
ARP070103903A
Other languages
English (en)
Inventor
Amarjit Singh
Sarabjit Singh
Shivanand Puthli
Rajendra Tandale
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of AR062644A1 publication Critical patent/AR062644A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Abstract

La presente invencion se relaciona con un sistema para el suministro espacial y temporalmente programable de un agente activo. Cuando se suministra por vía oral, el sistema puede ser retenido en la region gástrica por un período prolongado. El sistema comprende un nucleo, una o más capas recubiertas sobre el nucleo y un espacio hueco pre-formado. La invencion también se refiere a un proceso para la preparacion del sistema y un método para tratar/prevenir enfermedades mediante el suministro del sistema de la invencion a un sujeto que lo necesita.
ARP070103903A 2006-09-04 2007-09-04 Tecnologia de suministro programable flotante AR062644A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1411MU2006 2006-09-04

Publications (1)

Publication Number Publication Date
AR062644A1 true AR062644A1 (es) 2008-11-19

Family

ID=39430167

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103903A AR062644A1 (es) 2006-09-04 2007-09-04 Tecnologia de suministro programable flotante

Country Status (16)

Country Link
US (1) US8277843B2 (es)
EP (1) EP2068844A4 (es)
JP (1) JP2010502591A (es)
KR (1) KR20090065524A (es)
CN (1) CN101511346B (es)
AR (1) AR062644A1 (es)
AU (1) AU2007323018B2 (es)
BR (1) BRPI0716481A2 (es)
CA (1) CA2661172A1 (es)
CL (1) CL2007002562A1 (es)
IL (1) IL197121A0 (es)
MX (1) MX2009002371A (es)
NO (1) NO20090807A (es)
RU (1) RU2420268C2 (es)
WO (1) WO2008062440A2 (es)
ZA (1) ZA200901162B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2009153635A1 (en) * 2008-06-19 2009-12-23 University Of Witwatersrand, Johannesburg A chronotherapeutic pharmaceutical dosage form
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
EP2457561A4 (en) * 2009-07-06 2014-03-05 Kyorin Seiyaku Kk TABLET HAVING A HOLLOW STRUCTURE
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20110177231A1 (en) * 2010-01-16 2011-07-21 Alexander Grinberg Nano-, Micro-, Macro- Encapsulation And Release Of Materials
US20110200671A1 (en) * 2010-02-17 2011-08-18 Sun Pharma Advanced Research Company Ltd. Method of treating a disease condition susceptible to baclofen therapy
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
GB201102148D0 (en) * 2011-02-08 2011-03-23 Ucl Business Plc Layered bodies, compositions containing them and processes for producing them
EP2731609A1 (en) * 2011-07-14 2014-05-21 APeT Holding B.V. Nicotinamide compositions and the therapeutic use thereof
EP3446685A1 (en) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
JP2016533864A (ja) * 2013-10-22 2016-11-04 キャプソ・ヴィジョン・インコーポレーテッド マルチ密度相を有するカプセル装置に用いられるシステム及び方法
CA2943728C (en) 2014-03-26 2020-03-24 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
AU2015274453A1 (en) 2014-06-11 2017-01-12 Massachusetts Institute Of Technology Enteric elastomers
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
EP3518902A4 (en) 2016-09-30 2020-07-08 Lyndra, Inc. STOMACH RESTORATION SYSTEMS FOR RETARD RELEASE OF ACTIVE SUBSTANCES
US11534404B2 (en) * 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
WO2019025869A1 (en) * 2017-07-31 2019-02-07 Teva Pharmaceutical Industries Limited GALENIC FORMS WITH CONTROLLED RELEASE MANUFACTURED IN ADDITIVE MANNER
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
WO2019126218A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
JP2022544239A (ja) * 2019-08-12 2022-10-17 マサチューセッツ インスティテュート オブ テクノロジー 治療薬の投与のための物品及び方法
TWI763036B (zh) * 2020-09-14 2022-05-01 王子賓 可膨脹微膠囊
AU2022241157A1 (en) 2021-03-15 2023-09-07 Epitomee Medical Ltd. Expandable devices for delivery of active agents to tissues
WO2024062466A1 (en) 2022-09-21 2024-03-28 Epitomee Medical Ltd. Controllably disintegrable self-expandable ingestible devices

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512411B2 (es) * 1974-03-12 1980-04-02
JPS5134879A (en) * 1974-09-19 1976-03-24 Eisai Co Ltd Bishochukuryushinoseizoho
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
JPH03101615A (ja) * 1989-09-14 1991-04-26 Sumitomo Pharmaceut Co Ltd 胃内滞留型持続性製剤
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
PT969821E (pt) * 1997-03-26 2003-10-31 Janssen Pharmaceutica Nv Pastilhas tendo um nucleo revestido com um antifungico e um polimero
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6050796A (en) 1998-05-18 2000-04-18 General Motors Corporation Vane pump
WO2001058424A1 (en) 2000-02-09 2001-08-16 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Floating drug delivery composition
JP2002370970A (ja) * 2001-06-12 2002-12-24 Sanwa Kagaku Kenkyusho Co Ltd 胃内浮遊型固形製剤及びその製造方法
WO2003005951A2 (en) * 2001-07-10 2003-01-23 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
EP1574534A1 (en) * 2004-03-11 2005-09-14 Rohm And Haas Company Polymer carriers and process

Also Published As

Publication number Publication date
AU2007323018A1 (en) 2008-05-29
EP2068844A4 (en) 2013-01-23
CA2661172A1 (en) 2008-05-29
RU2009112396A (ru) 2010-10-20
KR20090065524A (ko) 2009-06-22
WO2008062440A2 (en) 2008-05-29
BRPI0716481A2 (pt) 2014-03-18
US20100015224A1 (en) 2010-01-21
CN101511346A (zh) 2009-08-19
IL197121A0 (en) 2009-11-18
AU2007323018B2 (en) 2011-02-03
RU2420268C2 (ru) 2011-06-10
US8277843B2 (en) 2012-10-02
MX2009002371A (es) 2009-03-12
CN101511346B (zh) 2012-07-04
EP2068844A2 (en) 2009-06-17
CL2007002562A1 (es) 2008-02-08
NO20090807A (no) 2009-06-04
ZA200901162B (en) 2010-06-30
WO2008062440A3 (en) 2008-07-31
JP2010502591A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
AR062644A1 (es) Tecnologia de suministro programable flotante
AR062321A1 (es) Sistema de liberacion controlada y metodo para fabricarlo
MY150626A (en) Fast dissolving solid dosage form
CL2008000219A1 (es) Composicion farmaceutica de liberacion modificada que comprende a uno o mas ingredientes farmaceuticamente activos, con solubilidad dependiente del ph, un polimero controlador de la liberacion, agentes facilitadores de la gelificacion; procedimiento
CL2007003193A1 (es) Metodo para evitar o reducir la vasoconstriccion a continuacion de la administracion de un portador de oxigeno vasoactivo, que comprende oxido nitrico gaseoso y otro agente activo; composicion farmaceutica que comprende un inhibidor de fosfodiesteras
AR078417A1 (es) Composiciones de pelicula sublingual y bucal
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
PE20140255A1 (es) Tableta dispersable en forma oral
JP2014515038A5 (es)
SMT201200014B (it) Nalmefene cloridrato diidrato.
CL2011002968A1 (es) Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion.
PE20070618A1 (es) Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer
BR112012015749A2 (pt) processos para produção de um agente farmaceuticamente ativo
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
ECSP10010514A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
NI201100025A (es) Métodos de administración de las formulaciones tópicas antimicóticas para el tratamiento de las infecciones por hongos.
CR20110267A (es) Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
CL2015000375A1 (es) Composicion farmaceutica en forma de microparticulas que comprende un nucleo inerte y al menos una primera capa de principio activo; proceso de formacion de microparticulas; combinacion farmaceutica; kit farmaceutico; uso para tratar y/o prevenir edemas, enfermedades cardiovasculares, diabetes, hipertension, entre otras.
MX2008008413A (es) Composicion farmaceutica para el tratamiento de las enfermedades de las uñas.
AR081520A1 (es) Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo
MY191875A (en) Solid dosage form
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
DE502008002255D1 (de) Arzneimittel enthaltend Fraumenmantel zur Behandlung von Endometritis, Vaginitis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal